prulifloxacin

Subscribe to Selected New Research on prulifloxacin

30 relevant articles (5 outcomes, 11 trials/studies) found for this Bio-Agent

Description: structure given in first source

Also Known As:

6-fluoro-1-methyl-7-(4-(5-methyl-2-oxo-1,3-dioxelen-4-yl)methyl-1-piperazinyl)-4-oxo-4H-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid; NM 441; NM-441; NM441; 1H,4H-(1,3)Thiazeto(3,2-a)quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1-piperazinyl)-4-oxo-

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

2-Ring Heterocyclic Compounds

Quinolines: 57

Quinolones: 969

Fluoroquinolones: 1268

prulifloxacin: 30

Experts

1.	Allegra, Luigi: 2 articles (01/2007 - 01/2006)
2.	Serati, Maurizio: 1 article (07/2007)
3.	Ghezzi, Fabio: 1 article (07/2007)
4.	Uccella, Stefano: 1 article (07/2007)
5.	Cromi, Antonella: 1 article (07/2007)
6.	Salvatore, Stefano: 1 article (07/2007)
7.	Bolis, Pierfrancesco: 1 article (07/2007)
8.	Barbone, F: 1 article (06/2007)
9.	Selli, C: 1 article (06/2007)
10.	Mogorovich, A: 1 article (06/2007)

Related Diseases

1.	Chronic Bronchitis 01/01/2005 - "The findings from this lung penetration study could explain the efficacy of once-daily prulifloxacin 600mg observed in clinical trials conducted in patients with exacerbation of chronic bronchitis." 01/01/2007 - "Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis." 01/01/2006 - "Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis." 01/01/2002 - "Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis." 02/01/2006 - "A number of randomized, controlled clinical trials carried out in Europe demonstrated the efficacy of prulifloxacin in the treatment of urinary tract (acute uncomplicated and complicated) and respiratory tract infections (acute exacerbations of chronic bronchitis), in comparison with the most widely used drugs such as ciprofloxacin, co-amoxiclav and pefloxacin" Get all the results and reference details, order at left...
2.	Infection 03/01/2007 - "CONCLUSIONS: In patients undergoing transrectal ultrasound-guided prostate biopsy, antimicrobial prophylaxis with prulifloxacin, both in single shot and 5-day administration, was found to prevent infection, with good tolerability and acceptability by the patients." 11/01/2005 - "Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa." 12/01/1996 - "In conclusion, prulifloxacin (NM394) showed potent antibacterial activity against clinical isolates and potent therapeutic efficacy against experimental infection in spite of its lower AUCs compared with the reference drugs" 01/01/2006 - "In conclusion, the in vitro inhibitory and bactericidal activities exhibited by ulifloxacin and the favorable characteristics shown by its prodrug (prulifloxacin) in clinical trials, particularly indicate this drug for the treatment of lung and urinary infections." 12/01/1991 - "NM441 was three to seven times as effective as enoxacin in systemic infections" Get all the results and reference details, order at left...
3.	Urinary Tract Infections (Urinary Tract Infection) 10/01/2007 - "In this study, we focused on the therapeutic efficacy of prulifloxacin (PUFX) against Pseudomonas aeruginosa OP 14-210, isolated from a patient with complicated urinary tract infection" 06/01/2007 - "Minimum inhibitory concentrations (MICs) and mutant prevention concentrations (MPCs) of prulifloxacin against 30 strains of Escherichia coli isolated from urinary tract infections as well as the 'biological cost' related to acquisition of resistance to the same drug in 10 uropathogenic E" 06/01/2007 - "In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance." 03/01/2006 - "The in vitro activity of prulifloxacin against urinary pathogens and its high and prolonged urinary concentration following a single oral dose, suggest that for treatment of urinary prulifloxacin is an alternative to other flouroquinolones for treatment of urinary tract infections." 12/01/1996 - "These findings suggest that prulifloxacin may be a useful drug in the treatment of urinary tract infections." Get all the results and reference details, order at left...
4.	Respiratory Tract Infections (Respiratory Tract Infection) 02/01/2006 - "A number of randomized, controlled clinical trials carried out in Europe demonstrated the efficacy of prulifloxacin in the treatment of urinary tract (acute uncomplicated and complicated) and respiratory tract infections (acute exacerbations of chronic bronchitis), in comparison with the most widely used drugs such as ciprofloxacin, co-amoxiclav and pefloxacin" Get all the results and reference details, order at left...
5.	Prostatitis 06/01/2007 - "Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial." 06/01/2007 - "Ninety-six patients with chronic bacterial prostatitis (CBP) and evidence of infection were randomized to receive a 4-week oral course of either prulifloxacin (a new fluoroquinolone) 600 mg or levofloxacin 500 mg once daily" Get all the results and reference details, order at left...
23 Diseases and 30 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Ciprofloxacin (Cipro)
2.	NM 394
3.	Amoxicillin-Potassium Clavulanate Combination (Co-amoxiclav)
4.	Pefloxacin
5.	pazufloxacin
6.	biapenem (L 627)
7.	Ofloxacin (Levofloxacin)
8.	Quinolones
9.	gatifloxacin (Zymar)
10.	sparfloxacin (AT 4140)
145 Drugs and Important Bio-Agents and 15 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Suburethral Slings (Tension-Free Vaginal Tape)
2.	Antibiotic Prophylaxis
2 Therapies and Procedures and 1 more articles analyzed in the Research Interface, order at left...

Research Interface Subscription

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Searches
2 clicks from Disease to Drug to Evidence
Trial references
All the Positive Outcomes
Drug and Therapy searches
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface Subscription

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>